# A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

> **NCT04501614** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 11 (actual)

## Conditions studied

- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Ph+ Mixed Phenotype Acute Leukemia (MPAL)
- Philadelphia Chromosome-Like ALL (Ph-like ALL)

## Interventions

- **DRUG:** Ponatinib
- **DRUG:** Chemotherapy Agents

## Key facts

- **NCT ID:** NCT04501614
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-24
- **Primary completion:** 2023-12-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by Sponsor.
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501614, "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04501614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*